STOCK TITAN

[Form 4] USANA Health Sciences Inc Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

On 07/24/2025, USANA Health Sciences (USNA) director Frederic J. Winssinger filed a Form 4 showing the conversion of 1,058 restricted stock units (transaction code “M”) into the same number of common shares. The move increased his directly held common stock to 6,929 shares, up from 5,871, an 18% rise. No shares were sold.

Winssinger still owns 3,172 RSUs that vest in four equal 25 % tranches on 24 Jul 2025, 23 Oct 2025, 22 Jan 2026 and 23 Apr 2026. The filing lists a zero exercise price, typical for RSU settlement, and contains no additional corporate events or financial data. While modest, an insider increasing holdings is generally viewed as a constructive signal rather than a liquidity event.

Il 24/07/2025, il direttore di USANA Health Sciences (USNA), Frederic J. Winssinger, ha presentato un Modulo 4 che mostra la conversione di 1.058 unità di azioni vincolate (codice transazione “M”) nello stesso numero di azioni ordinarie. Questa operazione ha portato il suo numero di azioni ordinarie detenute direttamente a 6.929, rispetto alle 5.871 precedenti, con un aumento del 18%. Non sono state vendute azioni.

Winssinger possiede ancora 3.172 RSU che matureranno in quattro tranche uguali del 25% rispettivamente il 24 luglio 2025, 23 ottobre 2025, 22 gennaio 2026 e 23 aprile 2026. La dichiarazione indica un prezzo di esercizio pari a zero, tipico per la liquidazione delle RSU, e non riporta altri eventi societari o dati finanziari. Sebbene modesto, un aumento delle partecipazioni da parte di un insider è generalmente considerato un segnale positivo piuttosto che un evento di liquidità.

El 24/07/2025, el director de USANA Health Sciences (USNA), Frederic J. Winssinger, presentó un Formulario 4 que muestra la conversión de 1.058 unidades restringidas de acciones (código de transacción “M”) en el mismo número de acciones ordinarias. Esta acción incrementó sus acciones ordinarias directamente en propiedad a 6.929, desde 5.871, un aumento del 18%. No se vendieron acciones.

Winssinger aún posee 3.172 RSU que se consolidan en cuatro tramos iguales del 25% el 24 de julio de 2025, 23 de octubre de 2025, 22 de enero de 2026 y 23 de abril de 2026. La presentación indica un precio de ejercicio cero, típico para la liquidación de RSU, y no contiene eventos corporativos adicionales ni datos financieros. Aunque modesto, un aumento en las participaciones por parte de un insider generalmente se interpreta como una señal positiva en lugar de un evento de liquidez.

2025년 7월 24일, USANA Health Sciences(USNA) 이사 프레데릭 J. 윈싱거가 양식 4를 제출하여 1,058개의 제한 주식 단위(RSU)를 (거래 코드 “M”) 동일한 수의 보통주로 전환했음을 보고했습니다. 이로 인해 그가 직접 보유한 보통주 수는 5,871주에서 6,929주로 18% 증가했습니다. 주식은 매도되지 않았습니다.

윈싱거는 여전히 3,172개의 RSU를 보유하고 있으며, 이는 2025년 7월 24일, 2025년 10월 23일, 2026년 1월 22일, 2026년 4월 23일에 각각 25%씩 네 번에 걸쳐 베스팅됩니다. 제출서에는 RSU 정산에 일반적인 행사 가격 0이 명시되어 있으며 추가적인 기업 이벤트나 재무 데이터는 포함되어 있지 않습니다. 비록 규모는 작지만, 내부자가 보유 주식을 늘리는 것은 일반적으로 유동성 이벤트보다는 긍정적인 신호로 간주됩니다.

Le 24/07/2025, le directeur de USANA Health Sciences (USNA), Frederic J. Winssinger, a déposé un formulaire 4 indiquant la conversion de 1 058 unités d’actions restreintes (code transaction « M ») en un nombre identique d’actions ordinaires. Cette opération a porté ses actions ordinaires détenues directement à 6 929, contre 5 871 auparavant, soit une hausse de 18 %. Aucune action n’a été vendue.

Winssinger détient toujours 3 172 RSU qui seront acquises en quatre tranches égales de 25 % les 24 juillet 2025, 23 octobre 2025, 22 janvier 2026 et 23 avril 2026. Le dépôt mentionne un prix d’exercice nul, ce qui est typique pour le règlement des RSU, et ne contient aucun autre événement d’entreprise ou donnée financière. Bien que modeste, une augmentation des participations par un initié est généralement perçue comme un signal positif plutôt qu’un événement de liquidité.

Am 24.07.2025 reichte der Direktor von USANA Health Sciences (USNA), Frederic J. Winssinger, ein Formular 4 ein, das die Umwandlung von 1.058 eingeschränkten Aktienanteilen (Transaktionscode „M“) in die gleiche Anzahl von Stammaktien zeigt. Dadurch erhöhte sich sein direkt gehaltener Stammaktienbestand auf 6.929 Aktien, von zuvor 5.871, ein Anstieg um 18 %. Es wurden keine Aktien verkauft.

Winssinger besitzt weiterhin 3.172 RSUs, die in vier gleichen Tranchen zu je 25 % am 24. Juli 2025, 23. Oktober 2025, 22. Januar 2026 und 23. April 2026 fällig werden. Die Meldung gibt einen Ausübungspreis von null an, was für die Abwicklung von RSUs typisch ist, und enthält keine weiteren Unternehmensereignisse oder Finanzdaten. Obwohl bescheiden, wird eine Erhöhung der Beteiligung durch einen Insider allgemein als positives Signal und nicht als Liquiditätsereignis gewertet.

Positive
  • None.
Negative
  • None.

Insights

TL;DR – Minor insider buy; positive signal but immaterial to valuation.

Insider purchases, even small, tend to be read positively because they align management with shareholders. Here, a director added only 1,058 shares, lifting his stake to 6,929 shares (<≈0.03 % of USNA’s float, based on last 2024 10-K). There was no open-market purchase; it is an RSU conversion, so cash did not leave the insider’s pocket. Still, he chose to hold, not sell, implying confidence. From a materiality standpoint, the dollar value is limited and unlikely to influence USNA’s fundamentals or liquidity. Therefore, the event is neutral in impact but carries a mild positive signaling effect for sentiment-focused investors.

Il 24/07/2025, il direttore di USANA Health Sciences (USNA), Frederic J. Winssinger, ha presentato un Modulo 4 che mostra la conversione di 1.058 unità di azioni vincolate (codice transazione “M”) nello stesso numero di azioni ordinarie. Questa operazione ha portato il suo numero di azioni ordinarie detenute direttamente a 6.929, rispetto alle 5.871 precedenti, con un aumento del 18%. Non sono state vendute azioni.

Winssinger possiede ancora 3.172 RSU che matureranno in quattro tranche uguali del 25% rispettivamente il 24 luglio 2025, 23 ottobre 2025, 22 gennaio 2026 e 23 aprile 2026. La dichiarazione indica un prezzo di esercizio pari a zero, tipico per la liquidazione delle RSU, e non riporta altri eventi societari o dati finanziari. Sebbene modesto, un aumento delle partecipazioni da parte di un insider è generalmente considerato un segnale positivo piuttosto che un evento di liquidità.

El 24/07/2025, el director de USANA Health Sciences (USNA), Frederic J. Winssinger, presentó un Formulario 4 que muestra la conversión de 1.058 unidades restringidas de acciones (código de transacción “M”) en el mismo número de acciones ordinarias. Esta acción incrementó sus acciones ordinarias directamente en propiedad a 6.929, desde 5.871, un aumento del 18%. No se vendieron acciones.

Winssinger aún posee 3.172 RSU que se consolidan en cuatro tramos iguales del 25% el 24 de julio de 2025, 23 de octubre de 2025, 22 de enero de 2026 y 23 de abril de 2026. La presentación indica un precio de ejercicio cero, típico para la liquidación de RSU, y no contiene eventos corporativos adicionales ni datos financieros. Aunque modesto, un aumento en las participaciones por parte de un insider generalmente se interpreta como una señal positiva en lugar de un evento de liquidez.

2025년 7월 24일, USANA Health Sciences(USNA) 이사 프레데릭 J. 윈싱거가 양식 4를 제출하여 1,058개의 제한 주식 단위(RSU)를 (거래 코드 “M”) 동일한 수의 보통주로 전환했음을 보고했습니다. 이로 인해 그가 직접 보유한 보통주 수는 5,871주에서 6,929주로 18% 증가했습니다. 주식은 매도되지 않았습니다.

윈싱거는 여전히 3,172개의 RSU를 보유하고 있으며, 이는 2025년 7월 24일, 2025년 10월 23일, 2026년 1월 22일, 2026년 4월 23일에 각각 25%씩 네 번에 걸쳐 베스팅됩니다. 제출서에는 RSU 정산에 일반적인 행사 가격 0이 명시되어 있으며 추가적인 기업 이벤트나 재무 데이터는 포함되어 있지 않습니다. 비록 규모는 작지만, 내부자가 보유 주식을 늘리는 것은 일반적으로 유동성 이벤트보다는 긍정적인 신호로 간주됩니다.

Le 24/07/2025, le directeur de USANA Health Sciences (USNA), Frederic J. Winssinger, a déposé un formulaire 4 indiquant la conversion de 1 058 unités d’actions restreintes (code transaction « M ») en un nombre identique d’actions ordinaires. Cette opération a porté ses actions ordinaires détenues directement à 6 929, contre 5 871 auparavant, soit une hausse de 18 %. Aucune action n’a été vendue.

Winssinger détient toujours 3 172 RSU qui seront acquises en quatre tranches égales de 25 % les 24 juillet 2025, 23 octobre 2025, 22 janvier 2026 et 23 avril 2026. Le dépôt mentionne un prix d’exercice nul, ce qui est typique pour le règlement des RSU, et ne contient aucun autre événement d’entreprise ou donnée financière. Bien que modeste, une augmentation des participations par un initié est généralement perçue comme un signal positif plutôt qu’un événement de liquidité.

Am 24.07.2025 reichte der Direktor von USANA Health Sciences (USNA), Frederic J. Winssinger, ein Formular 4 ein, das die Umwandlung von 1.058 eingeschränkten Aktienanteilen (Transaktionscode „M“) in die gleiche Anzahl von Stammaktien zeigt. Dadurch erhöhte sich sein direkt gehaltener Stammaktienbestand auf 6.929 Aktien, von zuvor 5.871, ein Anstieg um 18 %. Es wurden keine Aktien verkauft.

Winssinger besitzt weiterhin 3.172 RSUs, die in vier gleichen Tranchen zu je 25 % am 24. Juli 2025, 23. Oktober 2025, 22. Januar 2026 und 23. April 2026 fällig werden. Die Meldung gibt einen Ausübungspreis von null an, was für die Abwicklung von RSUs typisch ist, und enthält keine weiteren Unternehmensereignisse oder Finanzdaten. Obwohl bescheiden, wird eine Erhöhung der Beteiligung durch einen Insider allgemein als positives Signal und nicht als Liquiditätsereignis gewertet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Winssinger Frederic J

(Last) (First) (Middle)
2944 N 44TH STREET
SUITE 250

(Street)
PHOENIX AZ 85018

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
USANA HEALTH SCIENCES INC [ USNA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/24/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/24/2025 M 1,058 A (1) 6,929 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (1) 07/24/2025 M 1,058 (2) (2) Common Stock 1,058 $0 3,172 D
Explanation of Responses:
1. Each restricted stock unit represents a contingent right to receive one share of USNA common stock.
2. Restricted Stock Units vest 25% on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026.
Remarks:
/s/ Joshua Foukas, Attorney-in-Fact 07/28/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Usana Health Sciences Inc

NYSE:USNA

USNA Rankings

USNA Latest News

USNA Latest SEC Filings

USNA Stock Data

549.75M
10.76M
42.19%
59.03%
4.45%
Packaged Foods
Medicinal Chemicals & Botanical Products
Link
United States
SALT LAKE CITY